

AXE NEUROSCIENCES

Alexa Pichet Binette, PhD

Professeure-chercheure adjointe au Département de pharmacologie et physiologie et Centre de recherche de l'Institut universitaire de gériatrie de Montréal



Insights from proteomics to study Alzheimer's disease

Amyloid and tau proteins are the main pathological hallmarks of Alzheimer's disease (AD) that start to deposit in the brain decades before the onset of any clinical symptom. Both proteins can be imaged in vivo in the brain using positron emission tomography (PET), which allows to study AD pathophysiology across the whole continuum of the disease, i.e. from the preclinical phase of the disease (before there is any symptom) up to the dementia stage. Still, to date, there is no cure to AD, and it is increasingly clear that the causes and manifestations of the disease are multi-factorial. My research combines multimodal imaging and novel fluid biomarkers, including proteomics, to better understand the mechanisms leading to cognitive decline and AD, and help to improve clinical diagnosis and prognosis.

Vendredi 6 février 2026
12h à 13h

R05.212A

Ou via Zoom :

<https://us06web.zoom.us/j/81550195751?pwd=7yQISEgaZRc56qX7oPG6pMDPoF59wq.1>

Meeting ID: 815 5019 5751

Passcode: 504258

Séminaire organisé par Nicole Leclerc

Information : Ève Beaulieu – eve.beaulieu.chum@ssss.gouv.qc.ca

Nicolas Lemmetti – nicolas.lemmetti.chum@ssss.gouv.qc.ca

L'AUDACE DE
CHERCHER
PLUS LOIN